News

CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of ...
A new study published in the Journal of American Medical Association showed that Rilzabrutinib decreased itching and hives ...
Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for the treatment of warm autoimmune hemolytic anemia (wAIHA) and IgG4 ...
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
Sanofi said that its Rilzabrutinib treatment was granted orphan drug designation, which is used in the U.S. by the Food and Drug Administration. The designation is a status assigned to a medicine ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer. There are currently ...